Spectral AI, Inc.

Spectral AI, Inc. is a Dallas-based predictive artificial intelligence (AI) company focused on medical diagnostics. Its core mission is to revolutionize wound care management by providing faster and more accurate treatment decisions through its proprietary DeepView® Wound Diagnostics System, aiming to "See the Unknown"® in tissue health. The company's headquarters are located at 2515 McKinney Avenue, Suite 1000, Dallas, TX 75201, United States.

The company's primary product is the DeepView® System, which utilizes proprietary AI algorithms and multi-spectral imaging technology to objectively distinguish between fully damaged, partially damaged, and healthy human tissue. This system delivers a binary prediction on a wound's capacity to heal, or not heal, by a specified future time point, providing clinicians with immediate, data-driven assessments. Spectral AI initially focuses on applications for burn indications and diabetic foot ulcers (DFU), with plans for expansion into other clinical areas. The company's business model includes both a software-as-a-service (SaaS) component for licensing and algorithmic updates, and the imaging device itself.

Spectral AI is a publicly traded company on NASDAQ under the ticker MDAI. Vincent S. Capone was appointed Chief Executive Officer effective February 9, 2026, with Dr. J. Michael DiMaio serving as Chairman of the Board. David McGuire was named Chief Financial Officer, effective May 4, 2026. The DeepView® System received FDA Breakthrough Device Designation in 2018, and the company submitted a De Novo request to the FDA for the system in June 2025, marking a significant step towards commercialization. In March 2026, Spectral AI was awarded an additional $31.7 million in BARDA funding, contributing to a total of $54.9 million committed to date under a contract potentially valued up to $150 million. The company was also recognized on TIME's list of World's Top HealthTech companies in 2025 and received the Small Business Innovator Award in April 2026.

Latest updates

Spectral AI Award Highlights Burn Wound Diagnostics Race

Event summary

  • Spectral AI received the ‘Small Business Innovator Award’ at the inaugural Texas Innovation Conference on April 22-23, 2026.
  • The award recognizes the company’s DeepView® System, an AI-driven diagnostic device for burn wounds.
  • Jason Dwight and Bob Spencer of Spectral AI accepted the award on behalf of the company.
  • Spectral AI submitted a De Novo clearance application for the DeepView System to the FDA in June 2025.

The big picture

Spectral AI's recognition underscores the growing trend of AI-powered diagnostics in specialized medical fields. The company's focus on burn wound care represents a niche application with potential for significant impact, but also limited addressable market. The award provides a short-term boost, but long-term success hinges on FDA approval and clinical adoption, both of which carry substantial risk.

What we're watching

Regulatory Approval
The success of Spectral AI's De Novo FDA clearance application will be a critical determinant of commercial viability and market access for the DeepView System, and the timeline for approval remains a key risk.
Clinical Adoption
How quickly clinicians integrate the DeepView System into standard burn wound care protocols will dictate revenue generation and the ability to demonstrate the promised cost savings.
Competitive Landscape
The award highlights Spectral AI's position, but the burn wound diagnostics space is likely to attract increased attention and investment, potentially intensifying competition for market share.

Spectral AI Schedules Q1 Earnings Call Amid Wound Care AI Race

Event summary

  • Spectral AI (MDAI) will report Q1 2026 financial results on May 12, 2026, after market close.
  • A conference call to discuss results is scheduled for May 12, 2026, at 5:00 pm ET.
  • The DeepView System is being developed as a predictive diagnostic device for burn wound assessment.
  • Spectral AI was named to TIME’s list of World’s Top HealthTech companies in 2025.

The big picture

Spectral AI operates in a rapidly evolving market for AI-powered medical diagnostics, specifically targeting the large and complex wound care sector. The company’s focus on burn wound assessment positions it within a niche with significant potential for improved patient outcomes and cost reduction, but faces competition from established players and emerging startups. The upcoming earnings call will be a key indicator of the company's progress in commercializing its DeepView System and achieving its ambitious goals.

What we're watching

Market Adoption
The success of Spectral AI’s DeepView System hinges on adoption rates within wound care facilities, and the Q1 results will provide initial insight into this critical factor.
Regulatory Pathway
The company's ability to secure and maintain regulatory approvals for the DeepView System will dictate its long-term commercial viability, and any delays or rejections could significantly impact its growth trajectory.
Competitive Landscape
The wound care AI diagnostics space is becoming increasingly competitive, and Spectral AI’s ability to differentiate its DeepView System and maintain a technological edge will be crucial for sustained market share.
CID: 2439